Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated via claimed linking group – bond – chelating agent,...
Reexamination Certificate
1999-07-20
2010-02-23
Rawlings, Stephen L (Department: 1643)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated via claimed linking group, bond, chelating agent,...
C424S183100, C530S387300, C530S387700, C530S388800, C530S391300, C530S391700
Reexamination Certificate
active
07666425
ABSTRACT:
The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed are four hybridoma cell lines, each of which produces a monoclonal antibody recognizing extracellular domains of prostate specific membrane antigens of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.
REFERENCES:
patent: 4454106 (1984-06-01), Gansow et al.
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4814275 (1989-03-01), Durda et al.
patent: 4855353 (1989-08-01), Kurami et al.
patent: 4863851 (1989-09-01), McEwan et al.
patent: 4863854 (1989-09-01), Mattes et al.
patent: 4885363 (1989-12-01), Tweedle et al.
patent: 5013645 (1991-05-01), Kim
patent: 5053503 (1991-10-01), Dean et al.
patent: 5057302 (1991-10-01), Johnson et al.
patent: 5118611 (1992-06-01), Smith et al.
patent: 5130118 (1992-07-01), Johnson et al.
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5198208 (1993-03-01), Berg et al.
patent: 5208324 (1993-05-01), Klaveness et al.
patent: 5217704 (1993-06-01), Johnson et al.
patent: 5227471 (1993-07-01), Wright, Jr.
patent: 5229289 (1993-07-01), Kjeldsen et al.
patent: 5314996 (1994-05-01), Wright, Jr.
patent: 5342924 (1994-08-01), Chang
patent: 5419893 (1995-05-01), Berg et al.
patent: 5474756 (1995-12-01), Tweedle et al.
patent: 5489525 (1996-02-01), Pastan
patent: 5531978 (1996-07-01), Berg et al.
patent: 5538866 (1996-07-01), Israeli et al.
patent: 5565562 (1996-10-01), Parker et al.
patent: 5578484 (1996-11-01), Horoszewicz
patent: 5599677 (1997-02-01), Dowell et al.
patent: 5639879 (1997-06-01), Mease et al.
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5674470 (1997-10-01), Tweedle et al.
patent: 5697902 (1997-12-01), Goldenberg
patent: 5763202 (1998-06-01), Horoszewicz
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5804602 (1998-09-01), Slusher et al.
patent: 5846519 (1998-12-01), Tweedle et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5863538 (1999-01-01), Thorpe et al.
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5935818 (1999-08-01), Israeli et al.
patent: 5958474 (1999-09-01), Lee et al.
patent: 5965132 (1999-10-01), Thorpe et al.
patent: 6004554 (1999-12-01), Thorpe et al.
patent: 6004555 (1999-12-01), Thorpe et al.
patent: 6022524 (2000-02-01), Maisano et al.
patent: 6036955 (2000-03-01), Thorpe et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6093399 (2000-07-01), Thorpe et al.
patent: 6136311 (2000-10-01), Bander
patent: 6143274 (2000-11-01), Tweedle et al.
patent: 6150508 (2000-11-01), Murphy et al.
patent: 6261535 (2001-07-01), Thorpe et al.
patent: 6331175 (2001-12-01), Goldenberg
patent: 6649163 (2003-11-01), Bander
patent: 6683162 (2004-01-01), Scheinberg et al.
patent: 6962981 (2005-11-01), Murphy et al.
patent: 7045605 (2006-05-01), Bander et al.
patent: 7163680 (2007-01-01), Bander
patent: 2004/0120958 (2004-06-01), Bander et al.
patent: 2004/0213791 (2004-10-01), Bander et al.
patent: 0 125 023 (1984-11-01), None
patent: 0 208 531 (1987-01-01), None
patent: 0 232 751 (1987-08-01), None
patent: 0 233 619 (1987-08-01), None
patent: 0 279 397 (1988-08-01), None
patent: 0 292 689 (1988-11-01), None
patent: 0 299 795 (1989-01-01), None
patent: 0 315 188 (1989-05-01), None
patent: 0 382 583 (1990-08-01), None
patent: 0 392 423 (1990-10-01), None
patent: 0 466 200 AW (1992-01-01), None
patent: 0 495 878 (1992-07-01), None
patent: 0 594 739 (1994-05-01), None
patent: 0 882 454 AZ (1998-12-01), None
patent: WO 86/06384 (1986-11-01), None
patent: WO 88/02635 (1988-04-01), None
patent: WO 89/00557 (1989-01-01), None
patent: WO 89/06979 (1989-08-01), None
patent: WO 91/07493 (1991-05-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 91/15466 (1991-10-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 93/19668 (1993-10-01), None
patent: WO 94/04702 (1994-03-01), None
patent: WO 94/09820 (1994-05-01), None
patent: WO 94/26297 (1994-11-01), None
patent: WO 95/26206 (1995-10-01), None
patent: WO 95/31444 (1995-11-01), None
patent: WO 96/08570 (1996-03-01), None
patent: WO 96/26272 (1996-08-01), None
patent: WO 96/39185 (1996-12-01), None
patent: WO 96/40245 (1996-12-01), None
patent: WO 97/32862 (1997-09-01), None
patent: WO 97/35616 (1997-10-01), None
patent: WO 99/43710 (1999-09-01), None
patent: WO 00/50457 (2000-08-01), None
patent: WO 00/52473 (2000-09-01), None
patent: WO 00/74729 (2000-12-01), None
Thomas et al., Antibodies, a practical approach, vol. 2, 1988.
Panka et al., Proc Natl Acad Sci USA vol. 85 3080-3084 May 1988.
Rudikoff et al., Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
Greenspan et al (Nature Biotechnology 7:936-937 (1999)).
Schlom, (“Molecular Foundations of Oncology”, Chapter 6, pp. 93-134, 1991).
Thomas et al. (Antibodies, A Practical Approach, vol. 2, 1988).
George et al. (Circulation. 1998; 97: 900-906).
Greenspan et al. (Nature Biotechnology. 1999; 7: 936-937).
Henry et al. (Cancer Res. Nov. 1, 2004; 64: 7995-8001).
McDevitt et al. (Cancer Res. Nov. 1, 2000; 60: 6095-6100).
Morris et al. (Clin. Cancer Res. Oct. 15, 2005; 11 (2): 7454-7461).
Kim et al. (Int. J. Cancer. (2002; 102: 428-434).
Stancoviski et al. (Proceedings of the National Academy of Science USA. 1991; 88: 8691-8695).
Xu et al. (Int. J. Cancer. 1993; 53: 401-408).
Jiang et al. (J. Biol. Chem. Feb. 11, 2005; 280 (6): 4656-4662).
De Santes et al. (Cancer Res. Apr. 1, 1992; 52: 1916-1923).
Kinoshita et al. (Prost. Cancer Prost. Dis. 2005; 8: 359-363).
Boyer et al. (Int. J. Cancer. 1999; 82: 525-531).
Press et al. (J. Immunol. Dec. 15, 1998; 141 (12): 4410-4417).
Reimer et al. (Mol. Immunol. 2005; 42: 1121-1124).
Pettersen et al. (J. Immunol. Jun. 15, 1999; 162 (12): 7031-7040).
Bernard et al. (Human Immunol. 1986; 17: 388-405).
Lewis et al. (Cancer Immunol. Immunther. 1993; 37: 255-263).
Russell et al. (Cancer Immunol Immunother. May 2004; 53(5): 411-421).
Shinnick et al. (J. Invest. Dermatol. Jul. 1984; 83 (1 Suppl): 112s-115s).
Li et al (Prostate Cancer Prostatic Dis. 2002; 5 (1): 36-46).
Chang et al., “Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neovasculature,”Cancer Res., 59:3192-3198 (1999).
Coleman et al., “Fundamental Immunology,” Wm. C. Brown Publishers, p. 76, (1989).
Harlow et al., “Antibodies: A laboratory manual”, Cold Spring Harbor Laboratory, pp. 139-243, (1988).
Heston, “Characterization and Glutamyl Preferring Carboxypeptidase Function of Prostate Specific Membrane Antigen: A Novel Folate Hydrolase” (Urology49 (Supp. 3A): 104-112; 106 (1997).
Horoszewicz et al. “Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients,”Anticancer Research, 7:927-936 (1987).
Israeli et al., “Expression of the Prostate-Specific Membrane Antigen”,Cancer Research, 54:1807-1811 (1994).
Israeli et al., “Molecular Cloning of a Complementary DNA Encoding a Prostate-Specific Membrane Antigen”,Cancer Research, 53:227-230 (1993).
Jain, R.K. “Vascular and interstitial barriers to delivery of therapeutic agents in tumors” Cancer and Metastasis Reviews, vol. 9, p. 253-266, (1990).
Liu, et al., “Constitutive and Antibody-Induced Internalization of Prostate-Specific Membrane Antigen,”Cancer Res. 58:4055-60 (1998).
Liu, et. al., “Monoclonal Antibodies to the Extracellular Domain of Prostate-specific Membrane Antigen also React with Tumor Vascular Endothelium,”Cancer Res. 57:3629-34 (1997).
Murphy et al., “Measurement
Cornell Research Foundation Inc.
Proskauer Rose LLP
Rawlings Stephen L
LandOfFree
Treatment and diagnosis of prostate cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment and diagnosis of prostate cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and diagnosis of prostate cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4223893